Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EBITDA (2018 - 2025)

Historic EBITDA for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$27.5 million.

  • X4 Pharmaceuticals' EBITDA rose 2026.38% to -$27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.9 million, marking a year-over-year decrease of 28207.07%. This contributed to the annual value of -$37.5 million for FY2024, which is 6297.9% up from last year.
  • X4 Pharmaceuticals' EBITDA amounted to -$27.5 million in Q3 2025, which was up 2026.38% from -$26.2 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year EBITDA high stood at $71.1 million for Q2 2024, and its period low was -$37.3 million during Q1 2024.
  • Moreover, its 5-year median value for EBITDA was -$25.6 million (2022), whereas its average is -$20.0 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 37553.96% in 2024, then crashed by 13689.3% in 2025.
  • Over the past 5 years, X4 Pharmaceuticals' EBITDA (Quarter) stood at -$29.1 million in 2021, then increased by 11.97% to -$25.6 million in 2022, then increased by 1.48% to -$25.2 million in 2023, then crashed by 41.73% to -$35.7 million in 2024, then rose by 22.98% to -$27.5 million in 2025.
  • Its last three reported values are -$27.5 million in Q3 2025, -$26.2 million for Q2 2025, and -$9.4 million during Q1 2025.